廖国清, 刘鹏辉, 曲怡梅, 王红梅, 李雷. 多西他赛联合顺铂化疗与三维适形放疗同步治疗局部晚期非小细胞肺癌的临床研究[J]. 中国肿瘤临床, 2008, 35(22): 1269-1271.
引用本文: 廖国清, 刘鹏辉, 曲怡梅, 王红梅, 李雷. 多西他赛联合顺铂化疗与三维适形放疗同步治疗局部晚期非小细胞肺癌的临床研究[J]. 中国肿瘤临床, 2008, 35(22): 1269-1271.
shu
LIAO Guo-qing, LIU Peng-hui, QU Yi-mei, WANG Hong-mei, LI lei. Docetaxel plus Cisplatin Chemotherapy with Concurrent Three Dimensional-Conformal Radiotherapy for Locally Advanced Non-small Cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 35(22): 1269-1271.
Citation: LIAO Guo-qing, LIU Peng-hui, QU Yi-mei, WANG Hong-mei, LI lei. Docetaxel plus Cisplatin Chemotherapy with Concurrent Three Dimensional-Conformal Radiotherapy for Locally Advanced Non-small Cell Lung Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 35(22): 1269-1271.
shu

多西他赛联合顺铂化疗与三维适形放疗同步治疗局部晚期非小细胞肺癌的临床研究

Docetaxel plus Cisplatin Chemotherapy with Concurrent Three Dimensional-Conformal Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

    摘要
  • 摘要: 目的: 探讨多西他赛加顺铂化疗同步三维适形放射治疗(three dimensional-conformal radiotherapy3DCRT)的近期疗效、生存期及生活质量。 方法: 198例局部晚期非小细胞肺癌患者非随机分2组,化疗与放疗序贯组,化疗与放疗同步组。2组病例均采用3DCRT计划,照射剂量70～74Gy,2～2.5Gy/次,3次/周。同步组:102例,多西他赛40mg/m2 d1、顺铂30mg/m2 d1,在放射治疗开始时同步进行,每周1次,共用4～5次。序贯组:96例,多西他赛60mg/m2 d1、顺铂80mg/m2 d1,每3周1次,2周期后行放疗。 结果: 同步组和序贯组的总有效率分别为62.74%(64/102)和40.62%(39/96),差异有显著性(P<0.01);中位生存时间分别为21.6个月,18.4个月,同步组优于序贯组,差异无显著性;两组毒性差异相似。 结论: 三维适形放疗联合周剂量多西他赛同步治疗局部晚期非小细胞肺癌近期疗效较好,能明显提高患者的生活质量,不良反应能为患者耐受。

     

    Abstract: Objective : To evaluate the efficacy of docetaxel plus cisplatin chemotherapy with concurrent three dimen-sional radiotherapy (3DCRT) in patients with locally advanced non-small cell lung cancer (NSCLC). Methods :A total of 198 patients with locally advanced lung cancer were divided into the sequential group (102 cases)and the concurrent group (96 cases). Both groups received 3DCRT radiotherapy with a total dose of 70~74Gy, 2.0~2.5Gy/fraction, 4~5 times per week. The patients in the concurrent group were treated with doc-etaxel (40mg/m2) d1 and cisplatin (30mg/m2) d1 weekly for 4~5 cycles. The patients in the sequential groupwere treated with docetaxel (60mg/m2) d1 and cisplatin (80mg/m2) d1 or carboplatin (300mg/m2) d1. The cyclewas repeated every 21 days. Radiotherapy was given after 2 cycles of chemotherapy. Results : The responserates of the concurrent group and the sequential group were 62.74% and 40.62%, respectively, with a statisti-cal significance (P<0.01). Median survival time was 21.6 months in the concurrent group and 18.4 months inthe sequential group. The side effects in both groups were similar. Conclusion : 3DCRT combined with concur-rent docetaxel plus cisplatin chemotherapy is well tolerated and can improve the quality of life in most patientswith locally advanced NSCLC

     

    • HTML全文
    • 参考文献(1)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回